Tag: alloy

[Alloy Therapeutics in Business Wire] Alloy Therapeutics and Normunity sign multi-program antibody discovery collaboration in immuno-oncology

BOSTON–(BUSINESS WIRE)–Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing. The collaboration will support the advancement of Normunity’s immune normalizers, antibody therapies designed to target novel mechanisms that free the body’s normal immunity to fight cancer, which are conceived through a unique biotech-academic collaboration with a renowned immuno-oncology university research lab. Read...

Read More

[Alloy Therapeutics in Business Wire] Alloy Therapeutics raises $42 million Series D financing to accelerate discovery technology development across biologic modalities

BOSTON–(BUSINESS WIRE)–Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala Capital and joined by return investors Thiel Capital, Presight Capital, Founders Fund, and other unnamed family offices and sovereign wealth funds. Alloy will use proceeds from the Series D financing to further support the drug discovery community with new pre-competitive drug discovery technologies in new biologic modalities and new partnership models designed to fuel innovation. Read...

Read More

[Alloy Therapeutics in Business Wire] Alloy Therapeutics Hires People Executive Trier Bryant as President of Venture Studio, 82VS

BOSTON–(BUSINESS WIRE)–Alloy Therapeutics, a biotechnology ecosystem company, welcomes Trier Bryant as President of 82VS, Alloy’s affiliated venture studio. Trier is a strategic executive leader with distinctive tech, Wall Street, and military experience spanning 15 years, and brings a people-first approach to leading and scaling the 82VS team and ecosystem of startup companies. Read...

Read More

[Alloy Therapeutics in Businesswire] Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies for Genetically Validated Targets in Ophthalmic Diseases

SOUTH SAN FRANCISCO, Calif. & LEXINGTON, Mass.–(BUSINESS WIRE)–Maze Therapeutics, a company focused on translating genetic insights into new medicines, and Alloy Therapeutics, a company developing platforms and services to enable drug discovery, today announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases. Read...

Read More
  • 1
  • 2

Latest from Twitter